 |
More than 25,000 Devices Implanted Worldwide from 2010-20251
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEBâ„¢ Aneurysm Embolization System. Since its introduction, the WEB device has transformed the treatment of wide-neck bifurcation aneurysms, offering physicians and patients a clinically proven, single-device solution – One and Done – with proven simplicity, proven safety and durability, proven for ruptured aneurysms* and proven innovation2-9. The WEB device was commercially launched in October 2010 after receiving its CE (Conformité Européenne) Mark in Europe. The first implant was performed by Prof. Joachim Klisch in Germany, paving the way for a new era in aneurysm treatment.
The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods.
Carsten Schroeder, President and CEO of Terumo Neuro, commented on this significant milestone: "The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes, reducing the need for multiple devices and lengthy procedures. As we celebrate this achievement, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care."
Transforming Aneurysm Treatment with the WEB Device
The WEB device is the world's first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that require stents and coils, this device minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety, with a single device. Key milestones and clinical highlights of Terumo Neuro's WEB embolization system include:
- Unparalleled Clinical Data: The WEB device has been studied in over 600 patients across seven GCP trials, accumulating more than 1,464 patient-years with zero recorded rebleeds in a WEB device-treated aneurysm.2-8
- Proven Long-Term Safety & Durability: The five-year follow-up data from the WEB-IT, WEBCAST and WEBCAST 2 trials reaffirmed the WEB system's sustained efficacy and safety, including 0% device-related morbidity and mortality.7,8
- Expanding Treatment Options: The introduction of the WEB 17 system, a lower profile system to treat smaller aneurysms, has further refined aneurysm treatment providing physicians with greater flexibility and precision for a wider range of cases.
The WEB device's continued evolution underscores Terumo Neuro's dedication to advancing neurovascular technology. With more than 25,000 patients treated with the WEB device worldwide, this intrasaccular device remains the trusted choice for physicians seeking a reliable, single-device solution for wide-neck bifurcation aneurysms.
About Terumo Neuro (Formerly MicroVention, Inc.)
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For full indications for use, visit: WEBâ„¢ Embolization System | Terumo Neuro
*Information provided may not represent the approved indication for use for each country/market. Please refer to the Instruction for Use (IFU) in the specific market/country that you are looking into.
References:
- Data on file, Terumo Neuro.
- Pierot L, Moret J, Barreau X, et al. Safety and efficacy of aneurysm treatment with WEB in the cumulative population of three prospective, multicenter series. J Neurointerv Surg. 2018;10(6):553-559.
- Arthur AS, Molyneux A, Coon AL, et al. The safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide-necked bifurcation aneurysms: final 12-month results of the pivotal WEB Intrasaccular Therapy (WEB-IT) Study. J Neurointerv Surg. 2019;11(9):924-930.
- Pierot L, Moret J, Turjman F, Herbreteau D, et al. WEB Treatment of Intracranial Aneurysms: Clinical and Anatomic Results in the French Observatory. AJNR. 2016.
- Spelle, L., et al. (2022) "Clinical Assessment of WEB device in Ruptured Aneurysms (CLARYS): 12-month angiographic results of a multicenter study." J NeuroIntervent Surg.
- Spelle, L., et al. (2024) "Clinical Evaluation of WEB 17 device in intracranial aneurysms (CLEVER): 1-year effectiveness results for ruptured and unruptured aneurysms." J NeuroIntervent Surg.
- Pierot L, Szikora I, Barreau X, et al. Aneurysm treatment with the Woven EndoBridge (WEB) device in the combined population of two prospective, multicenter series: 5-year follow-up. J Neurointerv Surg. 2023;15(6):552-557.
- Fiorella D, Molyneux A, Coon A, et al. Safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide necked bifurcation aneurysms: final 5 year results of the pivotal WEB Intra-saccular. Therapy study (WEB-IT). J Neurointerv Surg. 2023;15(12):1175-1180.
- Rai AT, Turner RC, Brotman RG, Boo S. Comparison of operating room variables, radiation exposure and implant costs for WEB versus stent assisted coiling for treatment of wide neck bifurcation aneurysms. Interv Neuroradiol. 2021;27(4):465-472.
WEBâ„¢ is a trademark of MicroVention, Inc., registered in the United States and other jurisdictions. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. ©2024 MicroVention, Inc. MM2034(i) WW 03/25
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com
More than 25,000 Devices Implanted Worldwide from 2010-20251
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEBâ„¢ Aneurysm Embolization System. Since its introduction, the WEB device has transformed the treatment of wide-neck bifurcation aneurysms, offering physicians and patients a clinically proven, single-device solution – One and Done – with proven simplicity, proven safety and durability, proven for ruptured aneurysms* and proven innovation2-9. The WEB device was commercially launched in October 2010 after receiving its CE (Conformité Européenne) Mark in Europe. The first implant was performed by Prof. Joachim Klisch in Germany, paving the way for a new era in aneurysm treatment.
The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods.
Carsten Schroeder, President and CEO of Terumo Neuro, commented on this significant milestone: "The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes, reducing the need for multiple devices and lengthy procedures. As we celebrate this achievement, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care."
Transforming Aneurysm Treatment with the WEB Device
The WEB device is the world's first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that require stents and coils, this device minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety, with a single device. Key milestones and clinical highlights of Terumo Neuro's WEB embolization system include:
- Unparalleled Clinical Data: The WEB device has been studied in over 600 patients across seven GCP trials, accumulating more than 1,464 patient-years with zero recorded rebleeds in a WEB device-treated aneurysm.2-8
- Proven Long-Term Safety & Durability: The five-year follow-up data from the WEB-IT, WEBCAST and WEBCAST 2 trials reaffirmed the WEB system's sustained efficacy and safety, including 0% device-related morbidity and mortality.7,8
- Expanding Treatment Options: The introduction of the WEB 17 system, a lower profile system to treat smaller aneurysms, has further refined aneurysm treatment providing physicians with greater flexibility and precision for a wider range of cases.
The WEB device's continued evolution underscores Terumo Neuro's dedication to advancing neurovascular technology. With more than 25,000 patients treated with the WEB device worldwide, this intrasaccular device remains the trusted choice for physicians seeking a reliable, single-device solution for wide-neck bifurcation aneurysms.
About Terumo Neuro (Formerly MicroVention, Inc.)
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For full indications for use, visit: WEBâ„¢ Embolization System | Terumo Neuro
*Information provided may not represent the approved indication for use for each country/market. Please refer to the Instruction for Use (IFU) in the specific market/country that you are looking into.
References:
WEBâ„¢ is a trademark of MicroVention, Inc., registered in the United States and other jurisdictions. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. ©2024 MicroVention, Inc. MM2034(i) WW 03/25
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment
|
Award-Winning Technology and Samsung Electronics Collaboration on Display
SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- Amorepacific participates in CES 2026, the world's largest IT and consumer electronics trade show taking place January 6 to 9 (local time) in Las Vegas, Nevada.
At the event, Amorepacific will unveil Skinsight™, recognized as a CES Innovation Award Honoree in the Beauty Tech category, alongside its "AI skin analysis and care solution" developed in collaboration with Samsung Electronics and beauty devices from its brand makeON.
Skinsight™, debuting at CES 2026, is a next-generation "electronic skin" platform co-developed with a research group from the Massachusetts Institute of Technology (MIT). The platform analyzes real-time skin-aging signals to predict aging and delivers personalized solutions tailored to individual needs. A sensor patch applied to the skin simultaneously measures multiple aging factors influenced by the exposome and lifestyle, with AI technology delivering customized care recommendations. The technology, which can track skin changes across diverse environments, will be featured at the Innovation Awards Showcase at Venetian Expo.
Amorepacific will also present its AI-powered skin analysis technology, integrated into Samsung Electronics' "AI Beauty Mirror." Using camera-based optical diagnostics, the technology precisely assesses pore condition, redness, pigmentation, and wrinkles, then recommends personalized skincare solutions based on a dataset of over 450,000 cases. Results from the analysis are incorporated into skincare solutions provided by makeON's ONFACE LED Mask, equipped with 3,770 micro red LEDs, and Skin Light Therapy 3S, a personalized skincare device for daily-use, offering immediate improvements in skin condition. The solution also provides a range of beauty experiences, including product recommendations and skincare guidance. The technology will be on display at Samsung Electronics' exclusive exhibit at Wynn and Encore Las Vegas.
"Amorepacific aims to lead the global beauty and wellness industry with holistic longevity solutions," said Hyojung Joo, Head of Digital Strategy Division at Amorepacific. "Building on the innovative technologies and products showcased at CES, we will continue to deliver integrated beauty experiences to customers worldwide."
Award-Winning Technology and Samsung Electronics Collaboration on Display
SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- Amorepacific participates in CES 2026, the world's largest IT and consumer electronics trade show taking place January 6 to 9 (local time) in Las Vegas, Nevada.
At the event, Amorepacific will unveil Skinsight™, recognized as a CES Innovation Award Honoree in the Beauty Tech category, alongside its "AI skin analysis and care solution" developed in collaboration with Samsung Electronics and beauty devices from its brand makeON.
Skinsight™, debuting at CES 2026, is a next-generation "electronic skin" platform co-developed with a research group from the Massachusetts Institute of Technology (MIT). The platform analyzes real-time skin-aging signals to predict aging and delivers personalized solutions tailored to individual needs. A sensor patch applied to the skin simultaneously measures multiple aging factors influenced by the exposome and lifestyle, with AI technology delivering customized care recommendations. The technology, which can track skin changes across diverse environments, will be featured at the Innovation Awards Showcase at Venetian Expo.
Amorepacific will also present its AI-powered skin analysis technology, integrated into Samsung Electronics' "AI Beauty Mirror." Using camera-based optical diagnostics, the technology precisely assesses pore condition, redness, pigmentation, and wrinkles, then recommends personalized skincare solutions based on a dataset of over 450,000 cases. Results from the analysis are incorporated into skincare solutions provided by makeON's ONFACE LED Mask, equipped with 3,770 micro red LEDs, and Skin Light Therapy 3S, a personalized skincare device for daily-use, offering immediate improvements in skin condition. The solution also provides a range of beauty experiences, including product recommendations and skincare guidance. The technology will be on display at Samsung Electronics' exclusive exhibit at Wynn and Encore Las Vegas.
"Amorepacific aims to lead the global beauty and wellness industry with holistic longevity solutions," said Hyojung Joo, Head of Digital Strategy Division at Amorepacific. "Building on the innovative technologies and products showcased at CES, we will continue to deliver integrated beauty experiences to customers worldwide."
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Amorepacific Showcases Innovative Technologies at CES 2026
